Literature DB >> 10525567

Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF.

R J Boots1, D L Paterson, A M Allworth, J L Faoagali.   

Abstract

A case of aspergillus tracheobronchitis following influenza A infection in an immunocompetent 35 year old woman is described that required prolonged mechanical ventilation for airways obstruction. Treatment included liposomal amphotericin, inhaled amphotericin, gamma interferon and GM-CSF. Liposomal amphotericin therapy was associated with reversible hepatosplenomegaly. Inhaled corticosteroids with continued antifungal therapy were used for the management of severe recurrent airway obstruction. After a prolonged course of treatment she survived with fixed airways obstruction unresponsive to corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525567      PMCID: PMC1745394          DOI: 10.1136/thx.54.11.1047

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Aspergillus Tracheobronchitis and Influenza A Co-infection in a Patient with AIDS and Neutropenia.

Authors:  Ji-Yong Lee; Eun-Jeong Joo; Joon-Sup Yeom; Jae-Uk Song; Seo-Hyung Yim; Dong-Suk Shin; Jung-Hee Yu; Deok-Yun Ju; Jae-Wan Yim; Young-Seok Song; Yoon-Jeong Sohn; Sung-Im Do
Journal:  Infect Chemother       Date:  2014-09-24

3.  Aspergillus tracheobronchitis in a mild immunocompromised host.

Authors:  Byung Ha Cho; Youngmin Oh; Eun Seok Kang; Yong Joo Hong; Hye Won Jeong; Ok-Jun Lee; You-Jin Chang; Kang Hyeon Choe; Ki Man Lee; Jin-Young An
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-11-28

Review 4.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

5.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 6.  Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature.

Authors:  Melisa M Shah; Eric I Hsiao; Carl M Kirsch; Amit Gohil; Supriya Narasimhan; David A Stevens
Journal:  Diagn Microbiol Infect Dis       Date:  2018-02-02       Impact factor: 2.803

7.  Invasive pseudomembranous upper airway and tracheal Aspergillosis refractory to systemic antifungal therapy and serial surgical debridement in an Immunocompetent patient.

Authors:  Shihan N Khan; Rashmi Manur; John S Brooks; Michael A Husson; Kevin Leahy; Matthew Grant
Journal:  BMC Infect Dis       Date:  2020-01-06       Impact factor: 3.090

8.  Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.

Authors:  Amar Safdar; Gilhen H Rodriguez
Journal:  Pharmacotherapy       Date:  2013-06-19       Impact factor: 4.705

Review 9.  COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion.

Authors:  Frank L van de Veerdonk; Roger J M Brüggemann; Shoko Vos; Gert De Hertogh; Joost Wauters; Monique H E Reijers; Mihai G Netea; Jeroen A Schouten; Paul E Verweij
Journal:  Lancet Respir Med       Date:  2021-05-26       Impact factor: 30.700

10.  Invasive aspergillosis after pandemic (H1N1) 2009.

Authors:  Asma Lat; Nahid Bhadelia; Benjamin Miko; E Yoko Furuya; George R Thompson
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.